section name header

Pronunciation

kas-po-FUN-gin

Classifications

Therapeutic Classification: antifungals

Pharmacologic Classification: echinocandins

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Protein Binding: 97%.

Metabolism/Excretion: Slowly and extensively metabolized; <1.5% excreted unchanged in urine.

Half-life: Polyphasic: beta.gifphase: 9–11 hr; gamma.gifphase: 40–50 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
IVunknownend of infusion24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: flushing, pruritus, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.

GI: liver enzymes, diarrhea, nausea, vomiting.

GU: serum creatinine.

Local: venous irritation at injection site.

Neuro: headache.

Resp: bronchospasm.
Misc: chills, fever, (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Route/Dosage

Hepatic Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Cancidas